GANIRELIX ACETATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GANIRELIX ACETATE (GANIRELIX ACETATE).
Gonadotropin-releasing hormone (GnRH) antagonist competitively blocks GnRH receptors on pituitary gonadotropes, reducing secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
| Metabolism | Primarily hepatically metabolized via peptide hydrolysis; no major CYP450 involvement. |
| Excretion | Renal (approximately 75% as unchanged drug and metabolites) and fecal (approximately 22%). |
| Half-life | Terminal elimination half-life is approximately 16.2 hours (range 11-19 hours) in healthy females; clinically supports once-daily dosing. |
| Protein binding | Approximately 90%, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Approximately 0.9 L/kg, indicating distribution primarily into extracellular fluid and some tissue binding. |
| Bioavailability | Subcutaneous: Approximately 100% (range 91-100%) relative to intravenous injection. |
| Onset of Action | Subcutaneous: Within 1 hour, serum gonadotropin levels begin to decline. |
| Duration of Action | Subcutaneous: Duration of suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) is approximately 12-24 hours, supporting daily administration during controlled ovarian hyperstimulation. |
250 mcg subcutaneously once daily starting on day 2 or 3 of menstrual cycle, continued until day of hCG administration.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. No data for severe renal impairment (CrCl < 30 mL/min). |
| Liver impairment | No clinical data for hepatic impairment. Use with caution in moderate to severe hepatic impairment. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | Not approved for use in geriatric patients. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GANIRELIX ACETATE (GANIRELIX ACETATE).
| Breastfeeding | Unknown if excreted in human breast milk; M/P ratio not available. Risk of adverse effects in infant due to potential hormonal activity. Use caution; avoid if possible. |
| Teratogenic Risk | Category X: Contraindicated in pregnancy. Animal studies show embryolethality and teratogenicity. Risk of fetal loss (first trimester) and potential malformations (all trimesters) due to hormonal disruption. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to ganirelix or any component","Known or suspected pregnancy","Lactation (not recommended due to potential neonatal effects)"]
| Precautions | ["Hypersensitivity reactions (urticaria, angioedema) have been reported","Ovarian hyperstimulation syndrome (OHSS) may occur with ART","Congenital abnormalities cannot be excluded; pregnancy should be excluded before use"] |
Loading safety data…
| Monitor for signs of pregnancy prior to initiation. If exposure occurs during pregnancy, ultrasound for fetal development and assess for pregnancy loss. |
| Fertility Effects | Inhibits ovulation; used in controlled ovarian stimulation. Reversibly impairs fertility during treatment; long-term reproductive effects not established. |